Home >> Healthcare Administration >> Pharmaceuticals >> Food & Beverage >>

Genital Herpes - Pipeline Review, H1 2014

Published: Apr-2014 | Format: PDF | Global Markets Direct | Number of pages: 69 | Code: MRS - 1001

This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Genital Herpes
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
The report reviews key players involved in the therapeutics development for Genital Herpes and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects 
A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Genital Herpes pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Genital Herpes
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Content

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Genital Herpes Overview 7
Therapeutics Development 8
Pipeline Products for Genital Herpes - Overview 8
Pipeline Products for Genital Herpes - Comparative Analysis 9
Genital Herpes - Therapeutics under Development by Companies 10
Genital Herpes - Therapeutics under Investigation by Universities/Institutes 12
Genital Herpes - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Genital Herpes - Products under Development by Companies 16
Genital Herpes - Products under Investigation by Universities/Institutes 17
Genital Herpes - Companies Involved in Therapeutics Development 18
Vical Incorporated 18
Agenus, Inc. 19
NanoViricides, Inc. 20
Flamel Technologies S.A. 21
Starpharma Holdings Limited 22
Foamix Ltd. 23
AiCuris GmbH & Co. KG 24
Profectus BioSciences, Inc. 25
Genital Herpes - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
acyclovir SR - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
HerpV Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
pritelivir - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
astodrimer - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
VCLHB-01 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
VCLHM-01 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ZEP-3 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
HerpeCide-I - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
HSV-2 Vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
acyclovir - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Genital Herpes Vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Therapeutic/Prophylactic Vaccine Program For Herpes Simplex Virus - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Drugs for Bacterial and Viral Infections - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Genital Herpes - Recent Pipeline Updates 53
Genital Herpes - Dormant Projects 58
Genital Herpes - Discontinued Products 59
Genital Herpes - Product Development Milestones 60
Featured News & Press Releases 60
Nov 07, 2013: Agenus’ HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 Trial 60
Oct 17, 2013: ALLIED HERPES PHASE I TRIAL PROGRESS UPDATE 61
Jun 19, 2013: Allied Healthcare Receives Ethical Approval To Commence Phase I Clinical Trial Of HSV-2 Vaccine 61
Feb 27, 2013: Agenus's HerpV Phase II Study To Treat Genital Herpes Completes Enrollment 62
Jan 29, 2013: AiCuris Surpasses 50% Enrollment Milestone In Phase II Trial For Herpes Drug Pritelivir 63
Nov 27, 2012: AiCuris Starts Second Clinical Efficacy Trial With pritelivir 63
Oct 23, 2012: Agenus Commences Phase II Study Of HerpV Vaccine For Treatment Of Genital Herpes 64
Aug 07, 2012: AiCuris To Present Data On AIC316 At International Herpesvirus Workshop 65
Apr 16, 2012: AiCuris To Report AIC316 Phase II trial Data At International Meetings 65
Sep 26, 2011: Agenus Announces Positive Phase I Study Results Of HerpV In Genital Herpes 66
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69"
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Genital Herpes Overview 7
Therapeutics Development 8
Pipeline Products for Genital Herpes - Overview 8
Pipeline Products for Genital Herpes - Comparative Analysis 9
Genital Herpes - Therapeutics under Development by Companies 10
Genital Herpes - Therapeutics under Investigation by Universities/Institutes 12
Genital Herpes - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Genital Herpes - Products under Development by Companies 16
Genital Herpes - Products under Investigation by Universities/Institutes 17
Genital Herpes - Companies Involved in Therapeutics Development 18
Vical Incorporated 18
Agenus, Inc. 19
NanoViricides, Inc. 20
Flamel Technologies S.A. 21
Starpharma Holdings Limited 22
Foamix Ltd. 23
AiCuris GmbH & Co. KG 24
Profectus BioSciences, Inc. 25
Genital Herpes - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
acyclovir SR - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
HerpV Vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
pritelivir - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
astodrimer - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
VCLHB-01 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
VCLHM-01 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ZEP-3 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
HerpeCide-I - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
HSV-2 Vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
acyclovir - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Genital Herpes Vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Therapeutic/Prophylactic Vaccine Program For Herpes Simplex Virus - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Drugs for Bacterial and Viral Infections - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Genital Herpes - Recent Pipeline Updates 53
Genital Herpes - Dormant Projects 58
Genital Herpes - Discontinued Products 59
Genital Herpes - Product Development Milestones 60
Featured News & Press Releases 60
Nov 07, 2013: Agenus’ HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 Trial 60
Oct 17, 2013: ALLIED HERPES PHASE I TRIAL PROGRESS UPDATE 61
Jun 19, 2013: Allied Healthcare Receives Ethical Approval To Commence Phase I Clinical Trial Of HSV-2 Vaccine 61
Feb 27, 2013: Agenus's HerpV Phase II Study To Treat Genital Herpes Completes Enrollment 62
Jan 29, 2013: AiCuris Surpasses 50% Enrollment Milestone In Phase II Trial For Herpes Drug Pritelivir 63
Nov 27, 2012: AiCuris Starts Second Clinical Efficacy Trial With pritelivir 63
Oct 23, 2012: Agenus Commences Phase II Study Of HerpV Vaccine For Treatment Of Genital Herpes 64
Aug 07, 2012: AiCuris To Present Data On AIC316 At International Herpesvirus Workshop 65
Apr 16, 2012: AiCuris To Report AIC316 Phase II trial Data At International Meetings 65
Sep 26, 2011: Agenus Announces Positive Phase I Study Results Of HerpV In Genital Herpes 66

Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69

List of Tables

Number of Products under Development for Genital Herpes, H1 2014 8
Number of Products under Development for Genital Herpes - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 13
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Genital Herpes - Pipeline by Vical Incorporated, H1 2014 18
Genital Herpes - Pipeline by Agenus, Inc., H1 2014 19
Genital Herpes - Pipeline by NanoViricides, Inc., H1 2014 20
Genital Herpes - Pipeline by Flamel Technologies S.A., H1 2014 21
Genital Herpes - Pipeline by Starpharma Holdings Limited, H1 2014 22
Genital Herpes - Pipeline by Foamix Ltd., H1 2014 23
Genital Herpes - Pipeline by AiCuris GmbH & Co. KG, H1 2014 24
Genital Herpes - Pipeline by Profectus BioSciences, Inc., H1 2014 25
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Stage and Target, H1 2014 28
Number of Products by Stage and Mechanism of Action, H1 2014 30
Number of Products by Stage and Route of Administration, H1 2014 32
Number of Products by Stage and Molecule Type, H1 2014 34
Genital Herpes Therapeutics - Recent Pipeline Updates, H1 2014 53
Genital Herpes - Dormant Projects, H1 2014 58
Genital Herpes - Discontinued Products, H1 2014 59
List of Figures

Number of Products under Development for Genital Herpes, H1 2014 8
Number of Products under Development for Genital Herpes - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 14
Comparative Analysis by Early Stage Products, H1 2014 15
Assessment by Monotherapy Products, H1 2014 26
Number of Products by Top 10 Target, H1 2014 27
Number of Products by Stage and Top 10 Target, H1 2014 28
Number of Products by Top 10 Mechanism of Action, H1 2014 29
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 30
Number of Products by Top 10 Route of Administration, H1 2014 31
Number of Products by Stage and Top 10 Route of Administration, H1 2014 32
Number of Products by Top 10 Molecule Type, H1 2014 33
Number of Products by Stage and Top 10 Molecule Type, H1 2014 34

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing